| Description | Tafamidis meglumine (Fx-1006A) is a Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade |
| In vitro | Tafamidis以负协同性（K(d)s约2 nM和约200 nM）选择性结合于四聚体的两个通常不被占用的甲状腺素结合位点，并动力学稳定TTR。 |
| Target activity | TTR:2.7-3.2 μM (EC50) |
| Synonyms | Fx-1006A, 他发米帝司甲葡胺 |
| molecular weight | 503.33 |
| Molecular formula | C21H24Cl2N2O8 |
| CAS | 951395-08-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 5.03 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Bulawa C E , Connelly S , Devit M , et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade[J]. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(24):p.9629-9634. 2. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.[J]. The New England journal of medicine, 2018. |